26876532|t|EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms
26876532|a|Several studies reported somatic mutations of many genes (MEN1, CTNNB1, CDKIs and others) in parathyroid adenoma, although with different prevalence. Recently, activating mutations of the EZH2 and ZFX oncogenes were identified in benign parathyroid adenoma by whole exome sequencing. The same mutations had been found in blood and ovary malignant tumours. On one hand, this result raised the hypothesis that these oncogenes may play a role in the onset of parathyroid tumour, but it would also suggest they may be involved in malignant, rather benign, parathyroid neoplasm. Our aim was to verify the occurrence of selected mutations of the EZH2 and ZFX genes in an Italian cohort of 23 sporadic parathyroid carcinomas, 12 atypical and 45 typical adenomas. DNA was extracted from paraffin-embedded tissues, PCR amplified and directly sequenced. No mutations were detected in the coding sequence and boundaries of both genes in any of the samples. Two polymorphisms of the EZH2 gene were identified with different prevalence: the rs2072407 variant was present in the 30 % of the samples, in keeping with the overall frequency in larger populations, while the rs78589034 variant, located close to the 5' end of the exon 16, was detected in only one proband with familial isolated hyperparathyroidism; we investigated the possible outcome on the splicing process. EZH2 and ZFX genes do not seem to have an impact on the onset of most parathyroid tumours, both benign and malignant, though further studies on larger cohorts of different ethnicity are needed.
26876532	0	4	EZH2	T028	C1333368
26876532	9	12	ZFX	T028	C1421578
26876532	13	22	oncogenes	T028	C0029016
26876532	26	45	malignant behaviour	T080	C0205282
26876532	49	70	parathyroid neoplasms	T191	C0030521
26876532	79	86	studies	T062	C0008972
26876532	96	113	somatic mutations	T049	C0544886
26876532	122	127	genes	T028	C0017337
26876532	129	133	MEN1	T028	C0694884
26876532	135	141	CTNNB1	T028	C1332803
26876532	143	148	CDKIs	T028	C0919539
26876532	164	183	parathyroid adenoma	T191	C0262587
26876532	199	208	different	T080	C1705242
26876532	209	219	prevalence	T081	C0220900
26876532	231	241	activating	T052	C1879547
26876532	242	251	mutations	T045	C0026882
26876532	259	263	EZH2	T028	C1333368
26876532	268	271	ZFX	T028	C1421578
26876532	272	281	oncogenes	T028	C0029016
26876532	301	307	benign	T080	C0205183
26876532	308	327	parathyroid adenoma	T191	C0262587
26876532	331	353	whole exome sequencing	T063	C3640077
26876532	364	373	mutations	T045	C0026882
26876532	392	397	blood	T031	C0005767
26876532	402	407	ovary	T023	C0029939
26876532	408	425	malignant tumours	T191	C0006826
26876532	463	473	hypothesis	T078	C1512571
26876532	485	494	oncogenes	T028	C0029016
26876532	518	523	onset	T080	C0332162
26876532	527	545	parathyroid tumour	T191	C0030521
26876532	597	606	malignant	T080	C0205282
26876532	615	621	benign	T080	C0205183
26876532	623	643	parathyroid neoplasm	T191	C0030521
26876532	649	652	aim	T078	C1947946
26876532	671	681	occurrence	T079	C2745955
26876532	694	703	mutations	T045	C0026882
26876532	711	715	EZH2	T028	C1333368
26876532	720	729	ZFX genes	T028	C1421578
26876532	736	743	Italian	T098	C0337810
26876532	744	750	cohort	T098	C0599755
26876532	757	765	sporadic	T079	C0205422
26876532	766	788	parathyroid carcinomas	T191	C0687150
26876532	793	801	atypical	T080	C0205182
26876532	809	816	typical	T080	C3538928
26876532	817	825	adenomas	T191	C0001430
26876532	827	830	DNA	T114,T123	C0012854
26876532	835	844	extracted	T061	C0185115
26876532	850	875	paraffin-embedded tissues	T024	C1519524
26876532	877	880	PCR	T063	C0032520
26876532	881	890	amplified	T067	C1521871
26876532	904	913	sequenced	T169	C1561491
26876532	915	917	No	T033	C0205160
26876532	918	927	mutations	T045	C0026882
26876532	933	941	detected	T033	C0442726
26876532	949	964	coding sequence	T114,T123	C0015295
26876532	969	979	boundaries	T114,T123	C1136191
26876532	988	993	genes	T028	C0017337
26876532	1008	1015	samples	T167	C0370003
26876532	1021	1034	polymorphisms	T045	C0678951
26876532	1042	1051	EZH2 gene	T028	C1333368
26876532	1057	1067	identified	T080	C0205396
26876532	1073	1082	different	T080	C1705242
26876532	1083	1093	prevalence	T081	C0033105
26876532	1099	1116	rs2072407 variant	T028	C0678941
26876532	1121	1128	present	T033	C0150312
26876532	1148	1155	samples	T167	C0370003
26876532	1177	1184	overall	T080	C1561607
26876532	1185	1194	frequency	T079	C0439603
26876532	1198	1204	larger	T081	C0549177
26876532	1205	1216	populations	T081	C0032659
26876532	1228	1246	rs78589034 variant	T028	C0678941
26876532	1269	1275	5' end	T114	C1254348
26876532	1283	1290	exon 16	T114,T123	C0015295
26876532	1296	1304	detected	T033	C0442726
26876532	1317	1324	proband	T099	C1948021
26876532	1330	1338	familial	T169	C0241888
26876532	1339	1347	isolated	T169	C0205409
26876532	1348	1367	hyperparathyroidism	T047	C0020502
26876532	1372	1384	investigated	T169	C1292732
26876532	1398	1405	outcome	T169	C1274040
26876532	1413	1429	splicing process	T045	C0035687
26876532	1431	1435	EZH2	T028	C1333368
26876532	1440	1449	ZFX genes	T028	C1421578
26876532	1473	1479	impact	T080	C4049986
26876532	1487	1492	onset	T080	C0332162
26876532	1501	1520	parathyroid tumours	T191	C0030521
26876532	1527	1533	benign	T080	C0205183
26876532	1538	1547	malignant	T080	C0205282
26876532	1575	1581	larger	T081	C0549177
26876532	1582	1589	cohorts	T098	C0599755
26876532	1593	1602	different	T080	C1705242
26876532	1603	1612	ethnicity	T080	C0243103